$GLUE
Monte Rosa Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061995 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.728M $8.660M $7.020M
YoY Change -43.38% 23.36% 47.7%
% of Gross Profit
Research & Development $27.14M $28.31M $21.34M
YoY Change 9.12% 32.63% 41.2%
% of Gross Profit
Depreciation & Amortization $1.846M $1.834M $1.100M
YoY Change 72.52% 66.73% 89.0%
% of Gross Profit
Operating Expenses $34.86M $36.97M $28.36M
YoY Change 7.31% 30.34% 42.75%
Operating Profit -$36.97M -$28.36M
YoY Change 30.34% 42.75%
Interest Expense $1.589M $2.227M $997.0K
YoY Change -6.91% 123.37% 7569.23%
% of Operating Profit
Other Income/Expense, Net $2.254M $1.044M
YoY Change 115.9% 3267.74%
Pretax Income -$33.27M -$34.71M -$27.32M
YoY Change 8.1% 27.07% 37.71%
Income Tax -$22.00K $170.0K $0.00
% Of Pretax Income
Net Earnings -$33.25M -$34.88M -$27.32M
YoY Change 8.02% 27.7% 37.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.58 -$0.70 -$584.6K
COMMON SHARES
Basic Shares Outstanding 50.08M 49.81M 46.71M
Diluted Shares Outstanding 49.81M 46.73M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $232.4M $178.5M $272.1M
YoY Change -11.57% -34.42% -25.85%
Cash & Equivalents $128.1M $59.06M $112.4M
Short-Term Investments $104.3M $119.4M $159.8M
Other Short-Term Assets $3.294M $4.100M $5.529M
YoY Change -39.05% -25.85% 58.65%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $236.2M $182.9M $295.2M
YoY Change -14.38% -38.05% -20.32%
LONG-TERM ASSETS
Property, Plant & Equipment $33.80M $34.99M $19.38M
YoY Change 24.85% 80.52% 64.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $352.0K $270.0K $148.0K
YoY Change 26.62% 82.43% -91.44%
Total Long-Term Assets $67.54M $69.19M $62.37M
YoY Change 1.56% 10.94% 360.96%
TOTAL ASSETS
Total Short-Term Assets $236.2M $182.9M $295.2M
Total Long-Term Assets $67.54M $69.19M $62.37M
Total Assets $303.8M $252.1M $357.6M
YoY Change -11.28% -29.5% -6.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.15M $5.500M $9.753M
YoY Change 41.85% -43.61% 176.29%
Accrued Expenses $17.76M $17.10M $12.04M
YoY Change 0.31% 42.06% 30.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.59M $22.61M $21.79M
YoY Change 82.22% 3.76% 71.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $77.91M $45.00M $44.72M
YoY Change 71.59% 0.62% 2134.93%
Total Long-Term Liabilities $77.91M $45.00M $44.72M
YoY Change 71.59% 0.62% 2134.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.59M $22.61M $21.79M
Total Long-Term Liabilities $77.91M $45.00M $44.72M
Total Liabilities $124.5M $67.58M $66.51M
YoY Change 75.42% 1.61% 351.11%
SHAREHOLDERS EQUITY
Retained Earnings -$365.9M -$332.6M -$199.8M
YoY Change 58.74% 66.47% 102.64%
Common Stock $547.9M $518.6M $493.4M
YoY Change 8.77% 5.1% 5.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $179.3M $184.5M $291.1M
YoY Change
Total Liabilities & Shareholders Equity $303.8M $252.1M $357.6M
YoY Change -11.28% -29.5% -6.89%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$33.25M -$34.88M -$27.32M
YoY Change 8.02% 27.7% 37.71%
Depreciation, Depletion And Amortization $1.846M $1.834M $1.100M
YoY Change 72.52% 66.73% 89.0%
Cash From Operating Activities $29.63M -$24.71M -$20.60M
YoY Change -223.68% 19.95% 15.77%
INVESTING ACTIVITIES
Capital Expenditures $1.689M $1.660M -$1.400M
YoY Change -76.77% -218.57% -20.23%
Acquisitions
YoY Change
Other Investing Activities $15.99M $37.29M $30.89M
YoY Change -134.25% 20.72% 46002.99%
Cash From Investing Activities $14.30M $35.62M $29.49M
YoY Change -126.51% 20.79% -1846.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.17M 1.100M -217.0K
YoY Change 23.19% -606.91% -100.74%
NET CHANGE
Cash From Operating Activities 29.63M -24.71M -20.60M
Cash From Investing Activities 14.30M 35.62M 29.49M
Cash From Financing Activities 25.17M 1.100M -217.0K
Net Change In Cash 69.10M 12.01M 8.672M
YoY Change -220.25% 38.49% -13.05%
FREE CASH FLOW
Cash From Operating Activities $29.63M -$24.71M -$20.60M
Capital Expenditures $1.689M $1.660M -$1.400M
Free Cash Flow $27.95M -$26.37M -$19.20M
YoY Change -189.48% 37.34% 19.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001826457
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40522
dei Entity Registrant Name
EntityRegistrantName
Monte Rosa Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3766197
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Harrison Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02118
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2643
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
GLUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50081023
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59055000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54912000
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
119422000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
207914000
CY2023Q3 us-gaap Other Receivables
OtherReceivables
294000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
7656000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4140000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4444000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
960000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
182911000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
275886000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34992000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27075000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29408000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
34832000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4522000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4318000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
270000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
278000
CY2023Q3 us-gaap Assets
Assets
252103000
CY2022Q4 us-gaap Assets
Assets
342389000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5500000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7862000
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14228000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14580000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2881000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3127000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
22609000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25569000
CY2023Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1453000
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1533000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43517000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43874000
CY2023Q3 us-gaap Liabilities
Liabilities
67579000
CY2022Q4 us-gaap Liabilities
Liabilities
70976000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50085167
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50065680
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49445802
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49323531
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
518610000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
503696000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1455000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1752000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-332636000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230536000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
184524000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
271413000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252103000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342389000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28306000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21342000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84137000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60193000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8662000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7020000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24311000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19702000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
36968000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
28362000
us-gaap Operating Expenses
OperatingExpenses
108448000
us-gaap Operating Expenses
OperatingExpenses
79895000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-36968000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28362000
us-gaap Operating Income Loss
OperatingIncomeLoss
-108448000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79895000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2227000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
997000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6966000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1774000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
27000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
63000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-151000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
293000
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-16000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
24000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
109000
CY2023Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0
CY2022Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-131000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2254000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1044000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6708000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2176000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34714000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27318000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101740000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77719000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
170000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
360000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34884000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
us-gaap Net Income Loss
NetIncomeLoss
-102100000
us-gaap Net Income Loss
NetIncomeLoss
-77719000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.7
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.7
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.58
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.58
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.06
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.06
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.67
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.67
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49814903
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49814903
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46732353
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46732353
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49533143
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49533143
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46666000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46666000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34884000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
us-gaap Net Income Loss
NetIncomeLoss
-102100000
us-gaap Net Income Loss
NetIncomeLoss
-77719000
CY2023Q3 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
14000
CY2022Q3 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
32000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
42000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
99000
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
-171000
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
176000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
-255000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
680000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34699000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27462000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101803000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78300000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
271413000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
14000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3974000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
345000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-32038000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243726000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
897000
CY2023Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
14000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4153000
CY2023Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
261000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
303000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35178000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
213654000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1101000
CY2023Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
14000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4468000
CY2023Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
171000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34884000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
184524000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153000
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
34000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2251000
CY2022Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
146000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23932000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
325875000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000
CY2022Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
33000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2873000
CY2022Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
358000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26469000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
302050000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79000
CY2022Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
32000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3214000
CY2022Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
176000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
13211000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
291092000
us-gaap Profit Loss
ProfitLoss
-102100000
us-gaap Profit Loss
ProfitLoss
-77719000
us-gaap Share Based Compensation
ShareBasedCompensation
12595000
us-gaap Share Based Compensation
ShareBasedCompensation
8338000
us-gaap Depreciation
Depreciation
4376000
us-gaap Depreciation
Depreciation
2675000
glue Noncash Lease Expense
NoncashLeaseExpense
0
glue Noncash Lease Expense
NoncashLeaseExpense
3202000
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-3177000
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-685000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-131000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
109000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2233000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
177000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-312000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2122000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-899000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2268000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1041000
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
39000
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
-50000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
9999000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-18000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73436000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68505000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17352000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5640000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
62000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
109000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
75637000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
290049000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45631000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
glue Proceedsfrommaturityofmarketablesecurities
Proceedsfrommaturityofmarketablesecurities
121800000
glue Proceedsfrommaturityofmarketablesecurities
Proceedsfrommaturityofmarketablesecurities
130300000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
74504000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-165280000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2016000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
328000
us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
303000
us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
296000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2319000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3387000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-233753000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60190000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351409000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63577000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117656000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59055000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112394000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
4522000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
5262000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63577000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117656000
glue Common Stock Issuance Costs In Accounts Payable
CommonStockIssuanceCostsInAccountsPayable
31000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13507000
glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
5128000
glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
3872000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1270000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4750000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-332600000
us-gaap Net Income Loss
NetIncomeLoss
-102100000
us-gaap Net Income Loss
NetIncomeLoss
-77700000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
178500000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5624000
CY2023Q3 glue Accrued Research And Development
AccruedResearchAndDevelopment
5175000
CY2022Q4 glue Accrued Research And Development
AccruedResearchAndDevelopment
3936000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2908000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
183718000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
263867000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
119615000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
199000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
119422000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
208363000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
478000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
207914000
glue Number Of Marketable Securities Held
NumberOfMarketableSecuritiesHeld
31
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
82300000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
45390000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33326000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10398000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6251000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34992000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27075000
glue Depreciation Expense
DepreciationExpense
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes depreciation expense incurred (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.511%;"></td> <td style="width:1.223%;"></td> <td style="width:1%;"></td> <td style="width:9.15%;"></td> <td style="width:1%;"></td> <td style="width:1.223%;"></td> <td style="width:1%;"></td> <td style="width:9.15%;"></td> <td style="width:1%;"></td> <td style="width:1.223%;"></td> <td style="width:1%;"></td> <td style="width:9.15%;"></td> <td style="width:1%;"></td> <td style="width:1.223%;"></td> <td style="width:1%;"></td> <td style="width:9.15%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;"> <td style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="6" style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">Three months ended<br/>September 30,</span></p></td> <td style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="6" style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">Nine months ended<br/>September 30,</span></p></td> <td style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">Depreciation expense</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">1,834</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">1,033</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">4,376</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Arial;min-width:fit-content;">2,675</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q3 us-gaap Depreciation
Depreciation
1834000
CY2022Q3 us-gaap Depreciation
Depreciation
1033000
us-gaap Depreciation
Depreciation
4376000
us-gaap Depreciation
Depreciation
2675000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6145000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5020000
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14228000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14580000
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
13000000
CY2023Q3 glue Receivable In Tenant Improvements
ReceivableInTenantImprovements
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
5552000
us-gaap Operating Lease Cost
OperatingLeaseCost
4857000
us-gaap Variable Lease Cost
VariableLeaseCost
1700000
us-gaap Variable Lease Cost
VariableLeaseCost
1128000
us-gaap Lease Cost
LeaseCost
7252000
us-gaap Lease Cost
LeaseCost
5985000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.099
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1871000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48488000
glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
2382000
glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
1181000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50085167
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50065680
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
-0
us-gaap Payments Of Dividends
PaymentsOfDividends
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9758871
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7649610
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7436339
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.14
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12440000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3241800
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.54
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
549508
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
639512
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.37
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9489119
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3401000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
9489119
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3401000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3700455
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2452000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12595000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8338000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34884000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
us-gaap Net Income Loss
NetIncomeLoss
-102100000
us-gaap Net Income Loss
NetIncomeLoss
-77719000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.70
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.70
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.58
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.58
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.06
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.06
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.67
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.67
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49814903
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49814903
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46732353
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46732353
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49533143
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49533143
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46666000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46666000
CY2023Q3 us-gaap Pension Expense
PensionExpense
251000
CY2022Q3 us-gaap Pension Expense
PensionExpense
210000
us-gaap Pension Expense
PensionExpense
702000
us-gaap Pension Expense
PensionExpense
612000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
99000
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
72000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
488000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
407000

Files In Submission

Name View Source Status
0000950170-23-061995-index-headers.html Edgar Link pending
0000950170-23-061995-index.html Edgar Link pending
0000950170-23-061995.txt Edgar Link pending
0000950170-23-061995-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
glue-20230930.htm Edgar Link pending
glue-20230930.xsd Edgar Link pending
glue-ex10_2.htm Edgar Link pending
glue-ex31_1.htm Edgar Link pending
glue-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
glue-20230930_cal.xml Edgar Link unprocessable
glue-20230930_def.xml Edgar Link unprocessable
glue-20230930_lab.xml Edgar Link unprocessable
glue-20230930_pre.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
glue-20230930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable